Assembly Biosciences (ASMB) AI Stock Analysis

• Market Cap: $489.05M
• Dividend Yield: N/A
• Average Volume (3M): 164.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 31.30%
• EPS Growth: 32.79%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.72
• Shares Outstanding: 15,560,009
• 10 Day Avg. Volume: 178,321
• 30 Day Avg. Volume: 164,409
• PEG Ratio: 0.05
• Price to Book (P/B): 2.84
• Price to Sales (P/S): 3.32
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 1.79
• Enterprise Value/Gross Profit: 9.82
• Enterprise Value/Ebitda: -1.60
• 1Y Price Target: $41.75
• Price Target Upside: 12.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $36.00 ▼(-3.20% Downside)

Assembly Biosciences faces significant financial challenges, with no revenue and persistent losses, heavily impacting its overall score. While technical indicators show bullish momentum, overbought signals suggest caution. Poor valuation metrics further weigh down the score, making it a risky investment.

Positive Factors

Pipeline Progress

Assembly Biosciences' pipeline advancements, including interim antiviral activity and clinical outcomes, indicate strong potential for future product development and market success.

Equity Investment

The substantial equity investment strengthens Assembly Biosciences' financial position, enabling further development of key programs, which is crucial for long-term growth.

Clinical Data

Positive Phase 1b clinical data for ABI-4334 enhances Assembly Biosciences' credibility and potential to develop effective treatments for hepatitis B, supporting future growth.

Negative Factors

Revenue Absence

The absence of revenue over recent years highlights major financial instability, posing risks to Assembly Biosciences' ability to sustain operations and invest in R&D.

Negative Cash Flow

Persistent negative cash flow indicates liquidity challenges, potentially limiting Assembly Biosciences' capacity to fund ongoing operations and strategic initiatives.

Declining Equity

The significant decline in equity suggests weakening financial health and reduced buffer against financial distress, impacting long-term sustainability.

Assembly Biosciences Business Overview & Revenue Model

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

How the Company Makes Money

Assembly Biosciences generates revenue through a combination of research and development funding, collaborations and partnerships with other pharmaceutical companies, and potential future product sales. The company often enters into strategic alliances with larger biopharmaceutical firms to co-develop its drug candidates, which can provide upfront payments, milestone payments as development progresses, and royalties on future sales if the products are commercialized. Additionally, Assembly Biosciences may receive grants or funding from governmental or non-profit organizations to support its research initiatives. Their focus on HBV therapies positions them within a market that has significant unmet needs, which can enhance their potential for revenue generation once their products move through clinical trials and towards commercialization.

Assembly Biosciences Financial Statement Overview

Summary

Assembly Biosciences exhibits financial distress across key areas. The absence of revenue in recent years, combined with enduring net losses and negative cash flows, suggests significant profitability and liquidity challenges. While leverage remains low, declining equity and assets reflect potential financial instability, requiring strategic reassessment.

Income Statement

Assembly Biosciences has faced significant challenges with consistent revenue declines from $79.1M in 2020 to $0 in 2022 and 2024, indicating potential instability. The company has struggled with persistent net losses and negative profit margins, including a net profit margin of -100% in 2024. These factors highlight major profitability issues.

Balance Sheet

While the company maintains a reasonable equity ratio of 28% in 2024, indicative of some financial stability, the declining stockholders' equity from $240.6M in 2020 to $33.4M in 2024 raises concerns. A relatively low debt-to-equity ratio of 0.09 in 2024 suggests manageable leverage, but the shrinking equity indicates potential risk.

Cash Flow

Assembly Biosciences experiences significant volatility in free cash flow, with figures dropping sharply from $22.5M in 2023 to -$51.1M in 2024. The negative operating cash flow and free cash flow pose risks to future liquidity and financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.19M	28.52M	7.16M	0.00	6.25M	79.11M
Gross Profit	6.79M	28.52M	-41.74M	-69.08M	6.25M	-22.23M
EBITDA	-41.63M	-45.29M	-64.20M	-92.52M	-90.58M	-58.40M
Net Income	-38.55M	-40.18M	-61.23M	-93.09M	-129.85M	-62.15M
Balance Sheet
Total Assets	240.00M	119.17M	136.82M	101.79M	191.06M	283.25M
Cash, Cash Equivalents and Short-Term Investments	232.56M	112.08M	130.25M	91.61M	146.63M	216.41M
Total Debt	2.75M	3.09M	2.34M	3.46M	6.48M	10.13M
Total Liabilities	57.30M	85.81M	95.73M	19.13M	22.13M	42.68M
Stockholders Equity	182.69M	33.36M	41.10M	82.66M	168.93M	240.58M
Cash Flow
Free Cash Flow	-55.78M	-51.15M	22.49M	-84.56M	-96.49M	-65.18M
Operating Cash Flow	-55.74M	-51.12M	22.74M	-84.46M	-93.40M	-62.96M
Investing Cash Flow	-141.39M	40.17M	-69.14M	90.64M	26.52M	68.07M
Financing Cash Flow	191.21M	29.45M	13.82M	614.00K	53.06M	7.60M

Assembly Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 37.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 37.19 is above the 20-day moving average (MA) of 34.48, above the 50-day MA of 29.81, and above the 200-day MA of 19.37, indicating a bullish trend. The MACD of 2.40 indicates Negative momentum. The RSI at 65.41 is Neutral, neither overbought nor oversold. The STOCH value of 63.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASMB	51 Neutral	$489.05M	-5.62	-36.94%	―	31.30%	32.79%
QSI	49 Neutral	$339.40M	―	-52.44%	―	40.20%	-4.07%
BNTC	47 Neutral	$440.72M	―	-43.71%	―	―	80.95%
LXEO	38 Underperform	$702.87M	―	-80.69%	―	―	4.97%
ANNX	38 Underperform	$625.23M	―	-83.98%	―	―	-35.62%
VOR	33 Underperform	$162.26M	―	―	―	―	-1072.48%

Assembly Biosciences Corporate Events

Assembly Biosciences Inc. Reports Q3 2025 Earnings

Assembly Biosciences Inc., a biotechnology company based in South San Francisco, California, is focused on developing innovative therapeutics targeting serious viral diseases, including herpes simplex virus and hepatitis B and delta viruses. The company operates in the biotechnology sector and is known for its clinical-stage investigational therapies.

Assembly Biosciences Advances HSV-2 Treatment Study with ABI-1179

Study Overview: Assembly Biosciences Inc. is conducting a Phase 1a/1b study titled A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-1179, a potential treatment for recurrent genital herpes caused by HSV-2, highlighting its significance in addressing this common viral infection.

Assembly Biosciences’ Promising HSV-2 Treatment Study: Key Insights for Investors

Study Overview: Assembly Biosciences Inc. is conducting a Phase 1a/1b clinical study titled A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-5366, a potential treatment for recurrent genital herpes caused by HSV-2. This research is significant as it explores a new therapeutic option for a condition that affects millions globally.

Assembly Biosciences’ ABI-6250 Study: A Potential Game-Changer in Hepatitis Treatment

Assembly Biosciences Inc. is conducting a Phase 1a clinical study titled A Phase 1a, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-6250 in Healthy Subjects. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-6250, a potential treatment for Hepatitis Delta Virus and Hepatitis D, in healthy participants. This research is significant as it could lead to new therapeutic options for these conditions.